Healthcare · NSE: LUPIN · BSE: 500257
Lupin: how the business works
Lupin makes generic medicines for the US and branded medicines for India, earning ₹27,958 crore of revenue in FY26.
Follow Lupin
Email me when Lupin's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Lupin Limited · Mumbai, Maharashtra · Founded 1968
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹27,958 cr
- Profit to shareholders, FY26
- ₹5,333 cr
- US generic products sold, Q2 FY27
- 149
- Founded
- 1968
- Promoter holding, 30 Sep 2026
- 46.84%
The short version
Lupin in 5 points
1 · What it sells
Lupin makes generic medicines for the US and branded medicines for India, and its FY26 revenue from operations was ₹27,958 crore.
2 · Who pays it
In FY26, customers in the US paid 41.7% of Lupin's product revenue, customers in India 29.6% and customers in other countries 28.6%.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Lupin kept ₹18.8 as profit for shareholders, after ₹2.0 of one-off charges, mainly US antitrust provisions and a patent settlement.
4 · Where the operating profit comes from
Lupin does not report profit by country, but its Pharmaceuticals segment result was ₹7,050 crore in FY26, while its Others segment of diagnostics and digital health lost ₹178 crore.
5 · The one thing to watch
Lupin's US sales were US$317 million in Q2 FY27, against US$366 million in Q1 FY27, while management said on 4 Nov 2026 it expects FY27 US sales of US$1.1 billion to US$1.2 billion.
Sources: From Lupin's FY26 annual report, its FY26 and Q2 FY27 results filings and releases, and its Q1 FY27 call transcript · checked
Sources (7)
- Integrated Report (Annual Report) FY26
- Q4 FY26 and FY26 audited consolidated results (XBRL)
- Q3 FY26 consolidated results (XBRL), quarter to 31 Dec 2025
- Press release: Lupin Q2 FY2027 Results
- Press release: Lupin Q1 FY2027 Results
- Transcript of Q1 FY2027 earnings call (held 7 Aug 2026)
- Transcript of Q2 FY2027 earnings call (held 4 Nov 2026)
01Where the money goes · FY26
Where does ₹100 of Lupin's money go?
Lupin · FY26
Receipt for every ₹100
| Materials and goods bought for resale | ₹25.8 |
|---|---|
| Employee costs | ₹16.1 |
| Other running costs | ₹25.5 |
| Depreciation, amortisation and interest | ₹6.4 |
| One-off charges, net (mainly US antitrust provisions and a patent settlement) | ₹2.0 |
| Income tax | ₹5.3 |
| Minority shareholders' share of profit | ₹0.1 |
| Kept as profit for shareholders | ₹18.8 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Cityfort calculation from the FY26 results: each line ÷ total money in × 100. Money in = revenue of ₹27,958 crore + other income of ₹424 crore = ₹28,382 crore.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Lupin do?
Buyers in more than 100 markets, most of all the US and India, pay Lupin for its medicines. Materials, running costs and staff take most of the money, and ₹18.8 of every ₹100 that came in was left as profit in FY26.
- In FY26 customers in the US gave 41.7% of Lupin's product revenue, India 29.6% and other countries 28.6%.
- Of every ₹100 that came in during FY26, ₹25.8 went on materials and goods bought, ₹25.5 on other running costs and ₹16.1 on staff.
03Who pays it
Who pays Lupin?
Customers in the US
41.7%
of revenue
Buyers of Lupin's generic medicines in the US: ₹11,469 crore of FY26 product revenue, against ₹5,524 crore in FY22. The largest of them, not named, gave 10.5% of FY26 revenue.
Customers in India
29.6%
of revenue
Buyers in India of Lupin's prescription brands and drug ingredients: ₹8,148 crore of FY26 product revenue.
Customers in other countries
28.6%
of revenue
Buyers in Canada, Europe, emerging markets and other countries: ₹7,871 crore of FY26 product revenue.
- Customers in the US41.7%
- Customers in India29.6%
- Customers in other countries28.6%
Customer concentration
Lupin's largest customer, a US buyer it does not name, gave ₹2,948 crore in FY26, 10.5% of revenue from operations. That share was 5.3% in FY22, 5.8% in FY23, 7.1% in FY24 and 8.6% in FY25. Shares above are of product revenue by customer location (₹27,488 crore).
- Largest customer
- 11%
04How it makes money
How does Lupin make money?
Lupin's margins rose as its US sales grew from FY22 to FY26; when rival copies arrived in 2026, US sales fell.
Revenue grew 70% from FY22 to FY26 while staff costs grew 53%, and gross margin rose from 60.5% to 73.8% (Cityfort calculations). In Q2 FY27 US sales fell as competition rose for Tolvaptan and Mirabegron, the company said.
EBITDA margin (Cityfort calculation)
1.8%29.5%
FY22 to FY26
- Lupin files copies of off-patent medicines with the US FDA: 429 filings and 353 approvals by Q2 FY27.
- Some US launches had few rival copies for a time; 21 exclusive first-to-file applications were pending in Q2 FY27.
- US sales rose from US$944 million in FY25 to US$1,318 million in FY26.
- Revenue grew faster than staff costs, and EBITDA margin rose from 1.8% in FY22 to 29.5% in FY26 (Cityfort calculation).
- As competition rose for Tolvaptan and Mirabegron, US sales fell to US$317 million in Q2 FY27 from US$366 million in Q1, the company said.
- Profit pays for research (₹2,063 crore in FY26) on the next launches.
↺ Step 6 feeds back into step 1.
05Business segments · FY26
Which businesses make up Lupin?
USA
41.7%Product revenue from US customers, from the audited note on revenue by location. Lupin's audited segments are Pharmaceuticals (segment result ₹7,050 crore in FY26) and Others (a ₹178 crore loss), so profit by country is not reported.
Revenue ₹11,469 cr
India
29.6%Product revenue from customers in India, mostly prescription brands.
Revenue ₹8,148 cr
Other countries
28.6%Everything else. In the company's own FY26 sales figures, other developed markets were ₹3,244 crore, emerging markets ₹3,483 crore and drug ingredients sold worldwide ₹969 crore.
Revenue ₹7,871 cr
How the mix changed
- USA
- India
- Other countries
Revenue by segment, FY22 to FY26.
₹ crore
See the numbers
06The numbers · Consolidated · ₹ crore
How has Lupin done?
Revenue
₹27,958 crFY26
Revenue rose every year, from ₹16,406 crore in FY22 to ₹27,958 crore in FY26, and was ₹7,827 crore in Q2 FY27 against ₹8,277 crore in Q1 FY27.
₹ crore
See the numbers
Net profit
₹5,333 crFY26
Profit for shareholders went from a ₹1,528 crore loss in FY22, after a US antitrust settlement and write-downs, to ₹5,333 crore in FY26, after ₹558 crore of one-off charges.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹19.1FY26
EBITDA (Cityfort calculation, after one-off charges) rose from 1.8% of revenue in FY22 to 29.5% in FY26, and was 26.1% in Q2 FY27.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
₹5,280 crFY26
Free cash flow (cash from operations minus capital spending, from the audited annual reports) went from minus ₹538 crore in FY22 to ₹5,280 crore in FY26.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.
Sources (15)
- Q4 FY22 and FY22 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY23
- Q4 FY23 and FY23 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY24
- Q4 FY24 and FY24 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY25 (revised upload)
- Q4 FY25 and FY25 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY26
- Q4 FY26 and FY26 audited consolidated results (XBRL)
- Q3 FY25 consolidated results (XBRL), quarter to 31 Dec 2024
- Q1 FY26 consolidated results (XBRL), quarter to 30 Jun 2025
- Q2 FY26 consolidated results (XBRL), quarter to 30 Sep 2025
- Q3 FY26 consolidated results (XBRL), quarter to 31 Dec 2025
- Q1 FY27 consolidated results (XBRL), quarter to 30 Jun 2026
- Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026
07Who runs it
Who runs Lupin, and did they deliver?
Manju D. Gupta
Chairperson
Member of the founding Gupta family.
Vinita Gupta
Chief Executive Officer
Related to MD Nilesh Gupta; her FY26 pay was 428 times the median employee's.
Nilesh D. Gupta
Managing Director
Ramesh Swaminathan
Executive Director and Global Chief Financial Officer
What they said, and what happened
1 delivered · 4 too early to tell
Said on 13 Feb 2026
Management said FY26 EBITDA margin would be "in the range of 27% to 28%, higher than our earlier guidance".
DeliveredWhat happened
On 8 May 2026 management put FY26 EBITDA, excluding foreign-exchange gains and other income, at ₹8,160 crore, 29.7% of sales.
Said on 8 May 2026
Management said it expected FY27 top-line growth in "high-single digits with margins at around 25%".
Too early to tellWhat happened
H1 FY27 revenue was ₹16,104 crore, up 20.9%, including VISUfarma. The company's margin measure was 25.1% in Q2 FY27, and on 4 Nov 2026 it put FY27 guidance at around 24–25%.
Said on 7 Aug 2026
Management said it expected the FY27 US business in the "USD 1.1 billion to USD 1.2 billion range".
Too early to tellWhat happened
US sales were US$366 million in Q1 FY27 and US$317 million in Q2 FY27, US$683 million for the half year (Cityfort calculation); the range was repeated on 4 Nov 2026.
Said on 8 May 2026
Management said FY27 research spending would be "around 8% of sales" and the effective tax rate "about 25% - 26%".
Too early to tellWhat happened
In H1 FY27 research was 7.7% of sales and tax was 28.5% of profit before tax (Cityfort calculations); on 4 Nov 2026 management put the full-year tax rate at around 27–28%.
Said on 4 Nov 2026
Management said it expected to launch Apixaban oral suspension in the US "in the first quarter of FY28".
Too early to tellWhat happened
Not yet reported.
Sources (9)
- Integrated Report (Annual Report) FY26
- Transcript of Q3 FY2026 earnings call (held 13 Feb 2026)
- Transcript of Q4 FY2026 earnings call (held 8 May 2026)
- Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026
- Transcript of Q2 FY2027 earnings call (held 4 Nov 2026)
- Transcript of Q1 FY2027 earnings call (held 7 Aug 2026)
- Press release: Lupin Q1 FY2027 Results
- Press release: Lupin Q2 FY2027 Results
- Q1 FY27 consolidated results (XBRL), quarter to 30 Jun 2026
08What could go wrong
What could go wrong for Lupin?
- Competition
US prices fall when rivals launch
US sales were US$317 million in Q2 FY27, down 13.4% from Q1 FY27 in constant currency, as competition rose for Mirabegron and Tolvaptan. Management said on 4 Nov 2026 that margins were likely to moderate in the coming quarters.
Watch US sales in dollars each quarter (US$366 million in Q1 FY27, US$317 million in Q2 FY27).
- Regulation
US FDA inspections
Three sites were under remediation in Q2 FY27, and ICRA said two had outstanding FDA warning letters. The Goa plant's FDA inspection ended with a one-observation Form 483 on 23 Oct 2026.
Watch FDA inspection results and Lupin's filings on Tarapur, Mandideep, Pithampur and the Goa Form 483.
- Legal
US antitrust cases
The US generic-drug pricing investigation (since 2017) and state lawsuits (since 2019) are open; Lupin says it cannot estimate the possible loss. It booked ₹582 crore of provisions in FY26, and FY22's ₹1,528 crore loss included a ₹1,878 crore settlement in a separate US case over Glumetza.
Watch New provisions or settlements in the notes to each quarter's results.
- Concentration
One large US customer
Lupin's largest customer, an unnamed US buyer, gave 10.5% of FY26 revenue, up from 5.3% in FY22.
Watch The largest-customer share in each annual report.
- Pricing
Mirabegron licence costs and rivals
Lupin pays Astellas a per-unit licence fee on Mirabegron through Sep 2027, under the Feb 2026 settlement. Management said in Nov 2026 it expects more Mirabegron competition after Sep 2027.
Watch Mirabegron comments in each call and US sales after Sep 2027.
- Execution
Paying for acquisitions
Lupin paid ₹2,090 crore for VISUfarma in Apr 2026 and ₹370 crore to raise its Multicare Philippines stake to 99.89% in Jul 2026. Goodwill and other intangible assets rose to ₹7,941 crore on 30 Sep 2026 (Cityfort calculation).
Watch Other developed markets sales each quarter and any write-down of goodwill or intangibles.
- Currency
Currency swings
US customers gave 41.7% of FY26 product revenue. Foreign-exchange gains in the company's figures were ₹87 crore in Q2 FY27, against ₹204 crore in Q2 FY26.
Watch The rupee–dollar rate and the forex line in each results release.
Sources (13)
- Transcript of Q2 FY2027 earnings call (held 4 Nov 2026)
- Press release: Lupin Q2 FY2027 Results
- Press release: Lupin Q1 FY2027 Results
- Investor presentation Q2 FY2027
- ICRA rationale: Lupin Limited, [ICRA]A1+ reaffirmed (Rs 3,000 crore short-term facilities)
- Reg 30: US FDA inspection of Goa facility closed with Form 483 (one observation)
- Integrated Report (Annual Report) FY26
- Q4 FY26 and FY26 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY23
- Reg 30: Mirabegron settlement and licence agreement with Astellas
- Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026
- Reg 30: completion of VISUfarma B.V. acquisition
- Reg 30: agreement to acquire minority shareholding in Multicare Pharmaceuticals Philippines
09Supporters and critics
What do supporters and critics point to?
What supporters point to
- Revenue rose every year, from ₹16,406 crore in FY22 to ₹27,958 crore in FY26, and profit went from a ₹1,528 crore loss to ₹5,333 crore.
- Free cash flow was ₹5,280 crore in FY26, against ₹1,318 crore in FY25, from the audited annual reports.
- Cash and liquid investments were ₹2,047 crore more than borrowings on 30 Sep 2026 (Cityfort calculation), and ICRA reaffirmed [ICRA]A1+ in Jul 2026.
- India sales were ₹2,384 crore in Q2 FY27, up from ₹2,078 crore a year earlier.
- No promoter shares were pledged in any of the 12 quarters from Dec 2023 to Sep 2026.
What critics point to
- US sales fell to US$317 million in Q2 FY27 from US$366 million in Q1, and management said margins were likely to moderate.
- Q2 FY27 profit for shareholders was ₹1,155 crore, down from ₹1,478 crore a year earlier.
- Three sites were under FDA remediation in Q2 FY27, and the Goa inspection in Oct 2026 ended with a Form 483.
- FY26 profit came after ₹558 crore of one-off charges, mostly US antitrust provisions, and Lupin says it cannot estimate the possible loss from the open US cases.
- The largest customer's share of revenue rose from 5.3% in FY22 to 10.5% in FY26, and the CEO's FY26 pay was 428 times the median employee's.
10What to watch next
What should you watch next at Lupin?
Next event
Q3 FY27 results
12 Feb 2027
Expected, based on last year's date
US sales in dollars
US$317 million in Q2 FY27 and US$683 million for the half year; management's FY27 range, given on 7 Aug 2026, is US$1.1 billion to US$1.2 billion.
FDA plant status
Tarapur, Mandideep Unit-1 and Pithampur Unit-II were under remediation in Q2 FY27, and Goa got a one-observation Form 483 in Oct 2026.
Margins
The company's own EBITDA margin, excluding forex gains and other income, was 25.1% in Q2 FY27, against 31.3% a year earlier; its FY27 guidance, given on 4 Nov 2026, is around 24–25%.
11Key facts
Key facts about Lupin
- What does Lupin do?
- Lupin Ltd is a Mumbai-based drug maker founded in 1968. It sells generic medicines in the US and other countries and branded prescription medicines in India. Its FY26 revenue from operations was ₹27,958 crore, and it says it has 15 manufacturing sites and sells in more than 100 markets.
- How does Lupin make money?
- Lupin sells medicines. In its own FY26 sales figures, US sales were ₹11,678 crore (US$1,318 million), India ₹8,114 crore, emerging markets ₹3,483 crore, other developed markets ₹3,244 crore and active pharmaceutical ingredients (API) ₹969 crore.
- Who are Lupin's customers?
- By customer location, Lupin's FY26 product revenue came 41.7% from the US, 29.6% from India and 28.6% from other countries. Lupin's largest customer, a US buyer it does not name, gave ₹2,948 crore, 10.5% of Lupin's FY26 revenue from operations.
- How big is Lupin?
- Lupin's FY26 revenue from operations was ₹27,958 crore, up from ₹22,708 crore in FY25, and its profit for shareholders was ₹5,333 crore, up from ₹3,282 crore. Lupin says it employs more than 26,000 people.
- Who owns Lupin?
- On 30 Sep 2026 Lupin's promoter group held 46.84% of the shares. Foreign institutions held 23.28%, Indian institutions 23.78% (mutual funds 14.58%) and other shareholders 6.09%. No promoter shares were pledged.
- How did Lupin do in Q2 FY27?
- In Q2 FY27 (Jul–Sep 2026) Lupin's revenue was ₹7,827 crore, up from ₹7,048 crore a year earlier, and profit for shareholders was ₹1,155 crore, down from ₹1,478 crore. Lupin's US sales were US$317 million in Q2 FY27, against US$366 million in Q1 FY27.
- How much debt does Lupin have?
- On 30 Sep 2026 Lupin had borrowings of ₹5,496 crore and cash, bank deposits and current investments of ₹7,543 crore, so it held ₹2,047 crore more in cash than it owed (Cityfort calculation from the Q2 FY27 results). ICRA reaffirmed Lupin's short-term rating at [ICRA]A1+ on 8 Jul 2026.
- What dividend does Lupin pay?
- Lupin's board recommended a dividend of ₹18 per share for FY26, up from ₹12 for FY25 and ₹8 for FY24. The FY26 dividend was 15.4% of Lupin's FY26 basic earnings per share of ₹116.75 (Cityfort calculation).
Sources (11)
- Integrated Report (Annual Report) FY26
- Q4 FY26 and FY26 audited consolidated results (XBRL)
- Press release: Lupin Q2 FY2027 Results
- Press release: Lupin FY2026 and Q4 FY2026 Results
- Q4 FY25 and FY25 audited consolidated results (XBRL)
- Shareholding pattern as of 30 Sep 2026 (XBRL)
- Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026
- Q2 FY26 consolidated results (XBRL), quarter to 30 Sep 2025
- ICRA rationale: Lupin Limited, [ICRA]A1+ reaffirmed (Rs 3,000 crore short-term facilities)
- Integrated Report (Annual Report) FY25 (revised upload)
- Integrated Report (Annual Report) FY24
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Customer concentration
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Net debt
- Net profit
- Operating margin
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Lupin sell?
Generic medicines in the US
Off-patent medicines sold to US buyers: ₹11,678 crore in FY26 (US$1,318 million), against US$944 million in FY25. Lupin sold 149 generic products in the US in Q2 FY27, and says it was 3rd in US generics by prescriptions in Sep 2026 (IQVIA data).
Branded medicines in India
Brands that doctors in India prescribe: ₹8,114 crore in FY26. Lupin says it ranks 8th in the Indian medicine market (IQVIA, Sep 2026), 2nd in breathing (respiratory) and 3rd in heart (cardiac) medicines.
Other developed markets
Medicines sold in developed markets outside the US, including Canada and, since 1 Apr 2026, VISUfarma's eye-care brands in Italy, the UK, Spain, Germany and France: ₹3,244 crore in FY26.
Emerging markets
Medicines sold in emerging markets: ₹3,483 crore in FY26. On 1 Jul 2026 Lupin raised its stake in Multicare Pharmaceuticals Philippines from 56.28% to 99.89%.
Drug ingredients (API)
Active pharmaceutical ingredients, the chemical in a medicine that makes it work, sold to other drug makers: ₹969 crore in FY26, 3.5% of product sales.
Diagnostics and digital health
Lupin's 'Others' segment, which covers diagnostics, digital health and neuro-rehabilitation: ₹147 crore of revenue in FY26 and a segment loss of ₹178 crore.
What it does
- Does: Spent ₹2,063 crore on research and development in FY26, 7.5% of sales
- Does: Had 429 US generic applications filed and 353 approved by Q2 FY27, by its own count
- Does: Gives discounts, chargebacks and rebates: in FY26 they and other deductions took ₹17,064 crore off a contracted price of ₹44,552 crore (38.3%, Cityfort calculation)
- Does: Sells mostly long-term medicines in India: about 66% of H1 FY27 India sales were chronic medicines, the company says
What it does not do
- Does not: Does not report profit by country: its audited segments are Pharmaceuticals and Others
- Does not: Does not name its largest customer, a US buyer that gave 10.5% of FY26 revenue
- Does not: Was not a net borrower on 30 Sep 2026: cash and liquid investments exceeded borrowings (Cityfort calculation)
Sources (7)
- Press release: Lupin FY2026 and Q4 FY2026 Results
- Press release: Lupin Q2 FY2027 Results
- Investor presentation Q2 FY2027
- Reg 30: Nanomi B.V. agreement to acquire VISUfarma B.V.
- Reg 30: completion of VISUfarma B.V. acquisition
- Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026
- Integrated Report (Annual Report) FY26
13How the money flows
13How the money flows · FY26
How does money flow through Lupin?
Money in
- Revenue from operations₹27,958 cr
- Other income₹424 cr
The company
Lupin
₹28,382 cr came in
Money out
- Materials and goods bought for resale₹7,327 cr
- Employee costs₹4,575 cr
- Other running costs₹7,241 cr
- Depreciation, amortisation and interest₹1,810 cr
- One-off charges, net (mainly US antitrust provisions and a patent settlement)₹558 cr
- Income tax₹1,517 cr
- Minority shareholders' share of profit₹23 cr
- Net profit for Lupin shareholders₹5,333 cr
- In FY26 Lupin's medicines brought in ₹27,958 crore of revenue, and other income added ₹424 crore.
- Materials and goods bought for resale took ₹7,327 crore, staff ₹4,575 crore and other running costs ₹7,241 crore.
- Depreciation, amortisation and interest took ₹1,810 crore, and one-off charges ₹558 crore.
- Income tax took ₹1,517 crore, and minority shareholders in subsidiaries ₹23 crore.
- What was left for Lupin's shareholders was ₹5,333 crore of profit.
14What it needs to run
14What it needs to run
What does Lupin need to run?
Plants
15 manufacturing sites and 6 research centres, the company says. The FY26 annual report counts 12 plants in India and 3 abroad for Lupin Ltd itself.
US FDA approval
Each US generic needs the US Food and Drug Administration's approval, and each plant must pass FDA inspections. In Q2 FY27 the company listed three sites under remediation: Tarapur, Mandideep Unit-1 and Pithampur Unit-II.
Research
₹2,063 crore spent on research and development in FY26, 7.5% of sales; ₹618 crore in Q2 FY27, 7.9% of sales.
Doctors' visits
A sales force of about 11,400 people in India, about 8,800 of them medical representatives who call on doctors (Q2 FY27 presentation).
People
More than 26,000 people, the company says; Lupin Ltd itself had 20,113 permanent employees at the end of FY26.
Patent licences
To keep selling generic Mirabegron in the US, Lupin agreed on 10 Feb 2026 to pay Astellas US$90 million and a per-unit licence fee through Sep 2027.
15Where growth could come from
15Where growth could come from
Where could Lupin's growth come from?
On the Q2 FY27 call (4 Nov 2026) management gave FY27 margin guidance of "around 24–25%" on its own EBITDA measure and said margins were likely to moderate in the coming quarters. It also repeated the FY27 US sales range of US$1.1 billion to US$1.2 billion, first given on 7 Aug 2026.
US generics
MixedUS$317 million, Q2 FY27 (US$366 million in Q1)
US sales fell 13.4% from Q1 FY27 in constant currency as competition rose for Mirabegron and Tolvaptan, the company said. H1 FY27 US sales were US$683 million (Cityfort calculation).
Status: Mixed, partly on track.
India brands
Mixed₹2,384 crore, Q2 FY27 (+14.7%)
India sales rose from ₹2,078 crore in Q2 FY26 (Cityfort calculation of the growth). Management has said in every call since Feb 2026 that it aims to grow 1.2 to 1.3 times as fast as the Indian market. The company said its India business grew 14.7% in Q2 FY27, the same as the Indian market, and its chronic medicines 19.5% in H1 against the market's 17.2%.
Status: Mixed, partly on track.
Europe, Canada and VISUfarma
Working₹1,182 crore, Q2 FY27 (+45.7%)
Other developed markets rose from ₹812 crore in Q2 FY26; Q2 FY27 includes VISUfarma, bought on 1 Apr 2026, and Q2 FY26 does not (Cityfort calculation of the growth).
Status: Working, on track against what the company said.
Emerging markets
Behind₹891 crore, Q2 FY27 (−3.5%)
Emerging markets sales fell from ₹923 crore in Q2 FY26 (Cityfort calculation of the change).
Status: Behind, behind the company's own plan.
New US launches
EarlyMore than 60 launches planned over 3 years
Management said on 4 Nov 2026 it plans more than 60 US launches in the next three years, including about 25 injectable and respiratory products and 5 biosimilars, and expects to launch Apixaban oral suspension in Q1 FY28.
Status: Early, too early to judge.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (6)
16Financial strength and debt
16Financial strength · 30 Sep 2026
How much debt does Lupin have?
- Total debt₹5,496 cr
- Cash and investments₹7,543 cr
- Net cash (cash minus debt)₹2,047 cr
- Net worth (shareholders' money)₹24,051 cr
- Debt to equity
- 0.23×
- ₹ of debt for every ₹1 of shareholders' money
- Cash and liquid investments = cash, other bank balances and current investments; net debt = borrowings minus that (Cityfort calculation). Lease liabilities (₹706 crore on 31 Mar 2026) are not included.
- The company's own figure, whose definition it does not give, was net cash of ₹3,349 crore on 30 Sep 2026 and ₹4,636 crore on 31 Mar 2026. Management linked the fall to the VISUfarma purchase and dividend payments.
- Borrowings were ₹2,670 crore on 31 Mar 2024, ₹5,077 crore on 31 Mar 2025 and ₹5,910 crore on 31 Mar 2026.
- Goodwill and other intangible assets were ₹7,941 crore on 30 Sep 2026, against ₹5,866 crore on 31 Mar 2026, after the VISUfarma purchase (Cityfort calculation).
- Contingent liabilities on 31 Mar 2026 included ₹151 crore of income-tax claims and ₹635 crore of guarantees for subsidiaries; for the US antitrust cases the company says an estimate of possible loss cannot be made.
Sources (8)
- Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026
- Q4 FY26 and FY26 audited consolidated results (XBRL)
- Q4 FY25 and FY25 audited consolidated results (XBRL)
- Q4 FY24 and FY24 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY26
- Press release: Lupin Q2 FY2027 Results
- Press release: Lupin FY2026 and Q4 FY2026 Results
- Transcript of Q2 FY2027 earnings call (held 4 Nov 2026)
17Who owns it
17Who owns it · Q2 FY27
Who owns Lupin?
- Promoters (founders or parent company)46.8%
- Foreign institutions (FII)23.3%
- Indian institutions (DII)23.8%
- Public and others6.1%
Promoter pledge
No promoter shares were pledged in Q2 FY27.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (12)
- Shareholding pattern as of 31 Dec 2023 (XBRL)
- Shareholding pattern as of 31 Mar 2024 (XBRL)
- Shareholding pattern as of 30 Jun 2024 (XBRL)
- Shareholding pattern as of 30 Sep 2024 (XBRL)
- Shareholding pattern as of 31 Dec 2024 (XBRL)
- Shareholding pattern as of 31 Mar 2025 (XBRL)
- Shareholding pattern as of 30 Jun 2025 (XBRL)
- Shareholding pattern as of 30 Sep 2025 (XBRL)
- Shareholding pattern as of 31 Dec 2025 (XBRL)
- Shareholding pattern as of 31 Mar 2026 (XBRL)
- Shareholding pattern as of 30 Jun 2026 (XBRL)
- Shareholding pattern as of 30 Sep 2026 (XBRL)
18What it does with profit
18What it does with profit
What does Lupin do with its profit?
Dividend per share
₹18.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
No buybacks or fund raises in the period covered.
Sources (8)
- Integrated Report (Annual Report) FY23
- Q4 FY23 and FY23 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY24
- Q4 FY24 and FY24 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY25 (revised upload)
- Q4 FY25 and FY25 audited consolidated results (XBRL)
- Press release: Lupin FY2026 and Q4 FY2026 Results
- Q4 FY26 and FY26 audited consolidated results (XBRL)
19Governance signals
19Governance signals
What do Lupin's governance filings show?
- Auditor
- B S R & Co. LLP
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- Related-party amounts were not extracted for this page. The FY26 annual report says Chairperson Manju D. Gupta and CEO Vinita Gupta are related to Managing Director Nilesh D. Gupta.
- Credit rating
- ICRA [ICRA]A1+ (short-term, ₹3,000 crore of bank facilities), reaffirmed (outlook none (short-term rating only)), 8 Jul 2026
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
regulatory · 24 Oct 2026
US FDA findings at Tarapur, Mandideep, Pithampur and Goa
In Q2 FY27 the company listed Tarapur, Mandideep Unit-1 and Pithampur Unit-II as sites under remediation. ICRA said in Jul 2026 that Mandideep and Tarapur had outstanding FDA warning letters and that Pithampur was classified Official Action Indicated. An FDA inspection at Goa ended on 23 Oct 2026 with a Form 483 listing one observation.
other · 17 Apr 2026
US antitrust investigation and lawsuits
The US Department of Justice has investigated generic-drug pricing since Jan 2017, and US state attorneys general sued in May 2019; Lupin says an estimate of the possible loss cannot be made. Lupin booked ₹582 crore of antitrust provisions in FY26 and paid ₹316 crore in H1 FY27. On 17 Apr 2026 Lupin's US arm settled with Humana for US$30 million, denying the allegations.
auditor · 7 May 2026
Auditor to change after a full second term
B S R & Co. LLP signed the FY26 accounts and completes its second five-year term at the 2026 annual general meeting. On 7 May 2026 the board recommended Deloitte Haskins & Sells LLP for five years from that meeting.
other · 13 Jul 2026
Family-run, with high pay at the top
The Chairperson, CEO and Managing Director are members of the founding Gupta family. In FY26 the CEO's pay was 428 times the median employee's and the MD's 205 times.
Sources (8)
- Integrated Report (Annual Report) FY26
- Reg 30: appointment of Deloitte Haskins & Sells as statutory auditors
- ICRA rationale: Lupin Limited, [ICRA]A1+ reaffirmed (Rs 3,000 crore short-term facilities)
- Investor presentation Q2 FY2027
- Reg 30: US FDA inspection of Goa facility closed with Form 483 (one observation)
- Q4 FY26 and FY26 audited consolidated results (XBRL)
- Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026
- Reg 30: settlement with Humana in In Re Generic Pharmaceuticals Antitrust Litigation
20How it got here
20How it got here
How did Lupin get here?
1968
Milestone
Founded
Dr. Desh Bandhu Gupta founded Lupin in 1968.
2022
Crisis
A loss year
Lupin lost ₹1,528 crore in FY22 after a ₹1,878 crore US antitrust settlement over Glumetza and ₹840 crore of write-downs, mostly on the Solosec brand.
2024
Milestone
US sales recover
FY24 revenue rose 20.2% to ₹20,011 crore and profit to ₹1,915 crore; US product revenue rose from ₹5,158 crore to ₹7,105 crore.
2026
Crisis
Mirabegron patent case settled
After a US court upheld an Astellas patent on Myrbetriq (Mirabegron) in Apr 2025, Lupin settled on 10 Feb 2026 for US$90 million plus a licence fee through Sep 2027, and may keep selling.
2026
Milestone
Highest revenue and profit
FY26 revenue was ₹27,958 crore and profit ₹5,333 crore; US sales rose from US$944 million to US$1,318 million.
2026
Business-model change
VISUfarma bought
On 1 Apr 2026 Lupin completed the purchase of VISUfarma, an eye-care company with more than 60 brands in Europe, for €192.8 million (₹2,090 crore).
2026
Milestone
Philippines stake and oncology deal
On 1 Jul 2026 Lupin raised its stake in Multicare Pharmaceuticals Philippines to 99.89%. On 21 Jul 2026 it licensed two cancer drug programmes to Kaveri Therapeutics for an 82.2% stake.
Sources (14)
- Integrated Report (Annual Report) FY26
- Integrated Report (Annual Report) FY23
- Q4 FY22 and FY22 audited consolidated results (XBRL)
- Q4 FY24 and FY24 audited consolidated results (XBRL)
- Integrated Report (Annual Report) FY24
- Reg 30: US District Court (Delaware) order in Myrbetriq patent case
- Reg 30: Mirabegron settlement and licence agreement with Astellas
- Q4 FY26 and FY26 audited consolidated results (XBRL)
- Press release: Lupin FY2026 and Q4 FY2026 Results
- Reg 30: completion of VISUfarma B.V. acquisition
- Reg 30: Nanomi B.V. agreement to acquire VISUfarma B.V.
- Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026
- Reg 30: agreement to acquire minority shareholding in Multicare Pharmaceuticals Philippines
- Reg 30: oncology programmes licensed to Kaveri Therapeutics for an 82.2% stake
21Sources and changes
Where every number on this page comes from
Sources (45 documents)
- S1Integrated Report (Annual Report) FY26 · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 13 Jul 2026
- S2Integrated Report (Annual Report) FY25 (revised upload) · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 23 Jul 2025
- S3Integrated Report (Annual Report) FY24 · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 9 Jul 2024
- S4Integrated Report (Annual Report) FY23 · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 12 Jul 2023
- S5Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026 · NSE (company XBRL filing) · Tier 1: company or exchange filing · 4 Nov 2026
- S6Q1 FY27 consolidated results (XBRL), quarter to 30 Jun 2026 · NSE (company XBRL filing) · Tier 1: company or exchange filing · 6 Aug 2026
- S7Q4 FY26 and FY26 audited consolidated results (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 7 May 2026
- S8Q3 FY26 consolidated results (XBRL), quarter to 31 Dec 2025 · NSE (company XBRL filing) · Tier 1: company or exchange filing · 12 Feb 2026
- S9Q2 FY26 consolidated results (XBRL), quarter to 30 Sep 2025 · NSE (company XBRL filing) · Tier 1: company or exchange filing · 6 Nov 2025
- S10Q1 FY26 consolidated results (XBRL), quarter to 30 Jun 2025 · NSE (company XBRL filing) · Tier 1: company or exchange filing · 5 Aug 2025
- S11Q4 FY25 and FY25 audited consolidated results (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 15 May 2025
- S12Q3 FY25 consolidated results (XBRL), quarter to 31 Dec 2024 · NSE (company XBRL filing) · Tier 1: company or exchange filing · 12 Feb 2025
- S14Q4 FY24 and FY24 audited consolidated results (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 7 May 2024
- S15Q4 FY23 and FY23 audited consolidated results (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 10 May 2023
- S16Q4 FY22 and FY22 audited consolidated results (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 19 May 2022
- S18Press release: Lupin Q2 FY2027 Results · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 4 Nov 2026
- S19Press release: Lupin Q1 FY2027 Results · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 6 Aug 2026
- S20Press release: Lupin FY2026 and Q4 FY2026 Results · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 7 May 2026
- S26Investor presentation Q2 FY2027 · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 4 Nov 2026
- S27Transcript of Q2 FY2027 earnings call (held 4 Nov 2026) · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 6 Nov 2026
- S28Transcript of Q1 FY2027 earnings call (held 7 Aug 2026) · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 12 Aug 2026
- S29Transcript of Q4 FY2026 earnings call (held 8 May 2026) · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 14 May 2026
- S30Transcript of Q3 FY2026 earnings call (held 13 Feb 2026) · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 17 Feb 2026
- S31ICRA rationale: Lupin Limited, [ICRA]A1+ reaffirmed (Rs 3,000 crore short-term facilities) · ICRA Limited · Tier 2: rating agency or regulator · 8 Jul 2026
- S32Shareholding pattern as of 30 Sep 2026 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 19 Oct 2026
- S33Shareholding pattern as of 30 Jun 2026 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 21 Jul 2026
- S34Shareholding pattern as of 31 Mar 2026 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 20 Apr 2026
- S35Shareholding pattern as of 31 Dec 2025 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 20 Jan 2026
- S36Shareholding pattern as of 30 Sep 2025 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 17 Oct 2025
- S37Shareholding pattern as of 30 Jun 2025 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 18 Jul 2025
- S38Shareholding pattern as of 31 Mar 2025 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 16 Apr 2025
- S39Shareholding pattern as of 31 Dec 2024 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 15 Jan 2025
- S40Shareholding pattern as of 30 Sep 2024 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 8 Oct 2024
- S41Shareholding pattern as of 30 Jun 2024 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 12 Jul 2024
- S42Shareholding pattern as of 31 Mar 2024 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 11 Apr 2024
- S43Shareholding pattern as of 31 Dec 2023 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 11 Jan 2024
- S44Reg 30: Nanomi B.V. agreement to acquire VISUfarma B.V. · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 29 Sep 2025
- S45Reg 30: completion of VISUfarma B.V. acquisition · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 1 Apr 2026
- S46Reg 30: agreement to acquire minority shareholding in Multicare Pharmaceuticals Philippines · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 1 Apr 2026
- S47Reg 30: Mirabegron settlement and licence agreement with Astellas · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 10 Feb 2026
- S48Reg 30: settlement with Humana in In Re Generic Pharmaceuticals Antitrust Litigation · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 17 Apr 2026
- S49Reg 30: appointment of Deloitte Haskins & Sells as statutory auditors · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 7 May 2026
- S50Reg 30: US District Court (Delaware) order in Myrbetriq patent case · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 16 Apr 2025
- S51Reg 30: oncology programmes licensed to Kaveri Therapeutics for an 82.2% stake · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 21 Jul 2026
- S52Reg 30: US FDA inspection of Goa facility closed with Form 483 (one observation) · Lupin Ltd (filed with NSE/BSE) · Tier 1: company or exchange filing · 24 Oct 2026
Changes to this page (v1 · 16 Nov 2026)
- v1 · 16 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.